CRDF: 10-K Filing Prompts Model Update
By John Vandermosten, CFANASDAQ:CRDFREAD THE FULL CRDF RESEARCH REPORT2025 Financial ResultsCardiff (NASDAQ:CRDF) reported 2025 financial and operational results in a…
1,667€
4,58%
Echtzeit-Aktienkurs Cardiff Oncology
Bid:
Ask:
Nachrichten zur Cardiff Oncology Aktie
CRDF: New CEO Presents Phase II Readout
By John Vandermosten, CFANASDAQ:CRDFREAD THE FULL CRDF RESEARCH REPORTOn January 27th, 2026, Cardiff Oncology, Inc. (NASDAQ:CRDF) announced that its CEO,…
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript
…
CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response
By John Vandermosten, CFA NASDAQ:CRDFREAD THE FULL CRDF RESEARCH REPORTWe are initiating coverage of Cardiff Oncology, Inc.…
Cardiff Oncology: Preparing For A Defining 2026
…
Cardiff Oncology: Data Update Resolves Some Signals
…
Cardiff Oncology shares plunge after Q2 earnings miss By Investing.com
Cardiff Oncology shares plunge after Q2 earnings miss…
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do…
Cardiff Oncology (CRDF) Upgraded to Buy: Heres What You Should Know
Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
Cardiff Oncology: Buying The First-Line Onvansertib Strategy
…
Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon
…
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?
Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 16% and 11.85%, respectively, for the quarter ended December 2024. Do…
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
…
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
…
Cardiff Oncology Inc. (CRDF): Studiendaten, Kapitalerhöhung und Insiderkäufe!
Cardiff Oncology Inc. (CRDF) ist ein Biotech mit Fokus auf die Behandlung von Krebserkrankungen. PLK1 (Polo-like kinase 1) ist ein…
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
…
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy…
Cardiff Oncology: Beats Standard Of Care In First-Line Metastatic Colorectal Cancer
…
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
…
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
…
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
…
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
…
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
…
Cardiff Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 19.23% and 108%, respectively, for the quarter ended December 2023. Do…